Doseology Sciences Inc.

OTCPK:DOSE.F Stock Report

Market Cap: US$4.0m

Doseology Sciences Management

Management criteria checks 1/4

Doseology Sciences' CEO is Chris Jackson, appointed in May 2025, has a tenure of less than a year. directly owns 2.48% of the company’s shares, worth $98.02K. The average tenure of the management team and the board of directors is 1.2 years and 3.1 years respectively.

Key information

Chris Jackson

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownership2.5%
Management average tenure1.2yrs
Board average tenure3.1yrs

Recent management updates

Recent updates


CEO

Chris Jackson (55 yo)

less than a year
Tenure

Mr. Christopher Jackson, also known as Chris, is CEO & Director of Doseology Sciences Inc. from May 1, 2025. He was Interim Chief Executive Officer of Sensible Meats Inc. from May 2024 until May 17, 2024....


Leadership Team

NamePositionTenureCompensationOwnership
Daniel Vice
Co-Founder & Independent Directorno datano data1.04%
$ 41.2k
Christopher Cherry
Chief Financial Officer1.7yrsUS$9.89kno data
Christopher Jackson
CEO & Directorless than a yearno data2.48%
$ 98.0k
Timothy Corkum
President & COOless than a yearno datano data
Lindsay Hamelin
Corporate Secretary2.7yrsno datano data
1.2yrs
Average Tenure

Experienced Management: DOSE.F's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Daniel Vice
Co-Founder & Independent Director6.3yrsno data1.04%
$ 41.2k
Christopher Jackson
CEO & Directorless than a yearno data2.48%
$ 98.0k
Scott Reeves
Independent Director5.7yrsno data0.83%
$ 32.8k
Zahara Kanji-Aquino
Independent Director1.3yrsno datano data
David Lutz
Independent Director3.1yrsno datano data
Joseph Mimran
Member of Advisory Boardno datano datano data
3.1yrs
Average Tenure
55yo
Average Age

Experienced Board: DOSE.F's board of directors are considered experienced (3.1 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/08 11:58
End of Day Share Price 2026/01/05 00:00
EarningsN/A
Annual EarningsN/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Doseology Sciences Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.